Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Sponsor: Tor Biering-Sørensen
Summary
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.
Official title: A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Key Details
Gender
All
Age Range
50 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
285000
Start Date
2025-12-11
Completion Date
2026-08
Last Updated
2026-03-16
Healthy Volunteers
Yes
Conditions
Interventions
mRNA-1273 (Moderna COVID-19 vaccine)
For this arm, the current variant formulation of Spikevax (mRNA-1273) vaccine will be used.
Locations (2)
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Hellerup, Denmark
Danske Lægers Vaccinations Service
Søborg, Denmark